November 20, 2014 6:43 PM ET

Diversified Consumer Services

Company Overview of Mount Sinai School Of Medicine

Company Overview

Mount Sinai School of Medicine (MSSM) is a center for medical and scientific training.

One Gustave L. Levy Place

New York, NY 

United States

Founded in 1968

Key Executives for Mount Sinai School Of Medicine

Vice President of Technology and Business Development
Professor of Medicine
Compensation as of Fiscal Year 2014.

Mount Sinai School Of Medicine Key Developments

Mount Sinai School Of Medicine Presents at Citi's 9th Annual Biotech Conference, Sep-04-2014 09:00 AM

Mount Sinai School Of Medicine Presents at Citi's 9th Annual Biotech Conference, Sep-04-2014 09:00 AM. Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States. Speakers: Patrizia Cassaccia, M.D., Ph.D., Professor of Neuroscience & Genetics & Genomics.

DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn's Disease

DBV Technologies and the Icahn School of Medicine at Mount Sinai announced that they entered into a research collaboration agreement to investigate the efficacy and mechanism of epicutaneous tolerance utilizing Viaskin(R) for the treatment of Crohn's disease. Crohn's disease is a chronic condition for which there is currently no satisfactory cure able to increase the quality of life for people who have Crohn's disease. DBV has already proven, in several pre-clinical studies that repeated epicutaneous immunotherapy (EPIT(TM)) leads to increase natural and induced immune regulatory cells. Preliminary studies already showed that these immune regulatory cells play an essential role in by protecting the gut from inflammation. DBV partn ered with the Mount Sinai team, which has world-class expertise in cellular mechanisms involved in Crohn's disease, having already demonstrated that administration of Tregs to patients with severe Crohn's disease was well tolerated and efficacious. DBV has established that Induction of immune regulatory cells can be achieved by epicutaneous exposure. The combination of DBV's technology with Mount Sinai's expertise could lead to a first-in-class approach to induce tolerance and decrease gut inflammation. The Collaboration will explore a novel approach to treat Crohn's disease based on epicutaneous delivery with Viaskin(R) to induce regulatory cells (Treg). Pre-clinical studies will aim at: Evaluating the ability of epicutaneous tolerance induction with Viaskin(R) to treat inflammatory colitis; Demonstrating the functional ability of antigen-specific Tregs induced by epicutaneous exposure with Viaskin(R) in suppressing inflammatory responses in the gut; and Acquiring a better knowledge of cellular mechanisms involved. These activities and studies are expected to last at least 12 months.

Mount Sinai School Of Medicine Presents at BioPharm America 2013, Sep-17-2013 01:30 PM

Mount Sinai School Of Medicine Presents at BioPharm America 2013, Sep-17-2013 01:30 PM. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States. Speakers: Joel Dudley, Director of Biomedical Informatics.

Similar Private Companies By Industry

Company Name Region
Precision Collision Auto Body Inc. United States
Achieve, Inc. United States
Glaser Weil Fink Jacobs Howard Avchen & Shapiro LLP United States
Law Offices of Fred F. Mashian, APC United States
Aaron, Riechert, Carpol & Riffle, APC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mount Sinai School Of Medicine, please visit www.icahn.mssm.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.